{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:58:39Z","timestamp":1793923119405,"version":"4.8.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.cgh.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T01:11:10Z","timestamp":1532049070000},"page":"370-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases"],"prefix":"10.1016","volume":"17","author":[{"given":"Laurent","family":"Beaugerie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2314-9284","authenticated-orcid":false,"given":"Julien","family":"Kirchgesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2018.07.013_bib1","first-page":"1","article-title":"Changes in the leading cause of death: recent patterns in heart disease and cancer mortality","author":"Heron","year":"2016","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.cgh.2018.07.013_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cgh.2012.09.026","article-title":"Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010","volume":"11","author":"Jess","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib3","first-page":"1","article-title":"Deaths: final data for 2015","volume":"66","author":"Murphy","year":"2017","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.cgh.2018.07.013_bib4","unstructured":"Anon. Guidelines for preparing core clinical-safety information on drugs: report of CIOMS Working Group III \u2022 Council for International Organizations of Medical Sciences. Available at: https:\/\/cioms.ch\/shop\/product\/guidelines-preparing-core-clinical-safety-information-drugs-report-cioms-working-group-iii\/. Accessed February 21,\u00a02018."},{"key":"10.1016\/j.cgh.2018.07.013_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib6","doi-asserted-by":"crossref","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2018.07.013_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1365-2036.2009.03973.x","article-title":"Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine","volume":"29","author":"Seksik","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.07.013_bib10","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.07.013_bib12","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","article-title":"Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study","volume":"16","author":"Khan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib13","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.07.013_bib15","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.07.013_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2018.07.013_bib17","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.07.013_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib19","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1053\/j.gastro.2007.09.022","article-title":"Mortality by medication use among patients with inflammatory bowel disease, 1996-2003","volume":"133","author":"Hutfless","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jcv.2008.10.004","article-title":"Fatal varicella in an immunocompromised adult associated with a European genotype E2 variant of varicella zoster virus","volume":"44","author":"Springfeld","year":"2009","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.cgh.2018.07.013_bib21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jpeds.2011.04.045","article-title":"Association of Crohn\u2019s disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis","volume":"159","author":"Biank","year":"2011","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cgh.2018.07.013_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.07.013_bib23","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis","volume":"136","author":"Yiu","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib24","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.07.013_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.07.013_bib26","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cgh.2018.07.013_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib28","first-page":"195","article-title":"Cancers complicating inflammatory bowel disease","volume":"373","author":"Beaugerie","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.07.013_bib29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2018.07.013_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib31","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.13466","article-title":"Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"43","author":"Bourrier","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.07.013_bib33","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2018.07.013_bib34","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2018.07.013_bib35","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199305063281806","article-title":"Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis","volume":"328","author":"Kamel","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.07.013_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.gastro.2013.03.044","article-title":"Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib37","first-page":"1823","article-title":"Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn\u2019s disease: a prospective observational study","volume":"19","author":"Elriz","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.07.013_bib38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.cgh.2017.11.041","article-title":"High risk of anal and rectal cancer in patients with anal and\/or perianal Crohn\u2019s disease","volume":"16","author":"Beaugerie","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/liv.13548","article-title":"Inflammatory bowel disease with primary sclerosing cholangitis: a Danish population-based cohort study 1977-2011","volume":"38","author":"S\u00f8rensen","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2018.07.013_bib40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ecco-jcc\/jjv145","article-title":"Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA Registry","volume":"9","author":"Gordillo","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2018.07.013_bib41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apt.12294","article-title":"Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease","volume":"37","author":"Yuhara","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.07.013_bib42","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.cgh.2014.02.034","article-title":"Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases","volume":"12","author":"Ananthakrishnan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cgh.2014.07.017","article-title":"Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease","volume":"13","author":"Higgins","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib44","article-title":"Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease. A meta-analysis","author":"Sarlos","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2018.07.013_bib45","doi-asserted-by":"crossref","first-page":"e56944","DOI":"10.1371\/journal.pone.0056944","article-title":"Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death: a Danish nationwide cohort study","volume":"8","author":"Kristensen","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.cgh.2018.07.013_bib46","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","article-title":"Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study","volume":"67","author":"Kirchgesner","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.07.013_bib47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib48","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","article-title":"Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study","volume":"62","author":"Rungoe","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.07.013_bib49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2018.07.013_bib50","first-page":"A148","article-title":"Exposure to combination therapy with thiopurines and anti-TNF agents is associated with reduced incidence of acute arterial events in patients with inflammatory bowel disease (IBD): a nationwide French cohort study","volume":"5","author":"Kirchgesner","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2018.07.013_bib51","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2","volume":"32","author":"Roberts","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cgh.2018.07.013_bib52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cgh.2018.07.013_bib53","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn\u2019s disease: benefits outweigh the risk of lymphoma","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib54","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cgh.2014.07.058","article-title":"The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a Markov model","volume":"13","author":"Scott","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.07.013_bib55","doi-asserted-by":"crossref","first-page":"e0157191","DOI":"10.1371\/journal.pone.0157191","article-title":"Impact on life expectancy of withdrawing thiopurines in patients with Crohn\u2019s disease in sustained clinical remission: a lifetime risk-benefit analysis","volume":"11","author":"Kirchgesner","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.cgh.2018.07.013_bib56","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib57","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/ecco-jcc\/jjv167","article-title":"Health-related utility weights in a cohort of real-world Crohn\u2019s disease patients","volume":"9","author":"Greenberg","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2018.07.013_bib58","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1097\/MIB.0b013e3182916046","article-title":"A\u00a0systematic review of economic studies on biological agents used to treat Crohn\u2019s disease","volume":"19","author":"Tang","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.07.013_bib59","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/j.1572-0241.2008.02052.x","article-title":"Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.07.013_bib60","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1365-2036.2010.04302.x","article-title":"Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis","volume":"31","author":"Nicholls","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.07.013_bib61","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/MIB.0000000000001099","article-title":"Management of inflammatory bowel disease in the elderly patient: challenges and opportunities","volume":"23","author":"Ananthakrishnan","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.07.013_bib62","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2018.07.013_bib63","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib65","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.gastro.2016.08.067","article-title":"No excess cancer recurrence after immunosuppressive drugs in a meta-analysis of cohorts of patients with immune-mediated diseases: a mirage related to propensity bias?","volume":"152","author":"Beaugerie","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.07.013_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2010.04489.x","article-title":"Review article: explaining risks of inflammatory bowel disease therapy to patients","volume":"33","author":"Siegel","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.07.013_bib67","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1097\/MIB.0b013e31829aad16","article-title":"Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease","volume":"19","author":"Dulai","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.07.013_bib68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1539-6924.2008.01135.x","article-title":"Are adult patients more tolerant of treatment risks than parents of juvenile patients?","volume":"29","author":"Johnson","year":"2009","journal-title":"Risk Anal"},{"key":"10.1016\/j.cgh.2018.07.013_bib69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/MIB.0000000000000740","article-title":"Patients with ulcerative colitis are more concerned about complications of their disease than side effects of medications","volume":"22","author":"Thompson","year":"2016","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518307365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518307365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:27:04Z","timestamp":1761542824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356518307365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1542356518307365"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2018.07.013","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute","name":"copyright","label":"Copyright"}]}}